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Cannabinoids and Cannabinoid
Receptors: The Story so Far
Fred Shahbazi,1 Victoria Grandi,1 Abhinandan Banerjee,1 and John F. Trant1,*
Like most modern molecular biology and natural product chemistry, understanding cannabinoid pharmacology centers around molecular interactions, in this
case, between the cannabinoids and their putative targets, the G-protein coupled
receptors (GPCRs) cannabinoid receptor 1 (CB1) and cannabinoid receptor 2
(CB2). Understanding the complex structure and interplay between the partners
in this molecular dance is required to understand the mechanism of action of synthetic, endogenous, and phytochemical cannabinoids. This review, with 91 references, surveys our understanding of the structural biology of the cannabinoids
and their target receptors including both a critical comparison of the extant crystal structures and the computationally derived homology models, as well as an indepth discussion about the binding modes of the major cannabinoids. The aim is
to assist in situating structural biochemists, synthetic chemists, and molecular biologists who are new to the field of cannabis research.
INTRODUCTION
Despite its reputation, with the exception of D9-tetrahydrocannabinol (THC), the phytocannabinoids produced by Cannabis sativa are minimally psychoactive; however, they constitute a potentially rich source of
therapeutics owing to their interaction with central nervous system (CNS) receptors (Pertwee, 2006). THC
and cannabidiol (CBD) are by far the most abundant. THC was discovered in 1964, whereas the non-psychoactive CBD was discovered in 1942 (Reekie et al., 2017). Many of cannabis’ proposed medical benefits
are thought to arise from CBD; however, recent clinical and scientific work suggests that the minor cannabinoids also play an important role (Turner et al., 2017). Understanding the biological activity of these minor
components will guide plant breeding to develop new cultivars designed with particular medical applications in mind.
As of 2020, over 150 minor cannabinoids, collectively constituting less than 1% of the total dry mass of
cannabis bud, have been identified (Citti et al., 2019a). Cannabinoids isolated from cannabis sativa include
tetrahydrocannabivarin (THCV) (Gill, 1971), D9-tetrahydrocannabinolic acid (D9-THCa) (Rosenqvist and Ottersen, 1975), cannabidivarin (CBDV) (Vollner et al., 1969), D8-tetrahydrocannabinol (D8–THC) (Fahrenholtz
et al., 1966), cannabigerol (CBG) (El-Darawy et al., 1972), cannabigerovarin (CBGV) (Shoyama et al., 1975),
cannabinol (CBN) (El-Darawy et al., 1972), cannabinolic acid (CBNa) (Shoyama et al., 1970), cannabichromene (CBC) (El-Darawy et al., 1972), and cannabichromevarin (CBCV) (Shoyama et al., 1975) (Figure 1).
Most of these have been understudied; extant articles normally only describe their isolation and structure
determination: their biological activity remains unknown. Two human endocannabinoids have also been
identified: anandamide (AEA) from brain tissue and 2-arachidonoyl glycerol (2-AG) from peripheral tissue
(Reggio, 2010; Devane et al., 1992; Stella et al., 1997). The primary targets of the cannabinoids are thought
to be cannabinoid receptors 1 (CB1) and 2 (CB2), which are class A G-protein coupled receptors (GCPRs).
However, the structural similarity of GPCRs and the structural diversity of the phytocannabinoids, coupled
with the anecdotal and preliminary medical studies into the physiological effects of cannabis, hint at a
broader scope of interaction.
Exploring this exciting new landscape requires a thorough understanding of the known molecular interactions between cannabinoids and receptors; consequently, this review summarizes our existing knowledge
of the interactions between the cannabinoids and the two cannabinoid receptors, CB1 and CB2, based both
on structural biology and associated computational studies. As the first synthesis of the literature in this
field, we believe that it will prove as useful to the community as it has to us to better explore the molecular
pharmacology of these fascinating molecules. The target audience is natural product, computational and
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Figure 1. Structure of Cannabinoids Archetypal of Their Structural Families

synthetic chemists, as well as structural biologists and protein crystallographers seeking a background on
this field.

General Structure, Physiological Role, and Mechanism of Activation of GPCRs
GPCRs are a diverse family of eukaryote-specific membrane receptors that translate external signals, such
as light, peptides, lipids, sugars, and proteins, into specific cellular responses. Their centrality to cellular
signaling has made them arguably the central focus of modern drug discovery (Hauser et al., 2017).
GPCR domains comprise the extracellular N terminus, seven transmembrane alpha helices (TM), loops connecting the TMs, and an intracellular C terminus. Ligand binding generally occurs within a binding site gap
formed by the TM bundle, directly to a pocket formed by the extracellular loops, or to a combination of
extracellular loop and binding site gap residues. Binding induces a conformational change in the receptor,
causing activation of a G protein docked to the internal face (Figure 2), which then initiates a specific cellular
process (Latorraca et al., 2017; Weis and Kobilka, 2014). In general, an agonist-bound receptor activates an
appropriate G protein that promotes dissociation of GDP (Figure 2) (Tuteja, 2009). GPCR ligands fall into
four categories depending on the nature of their interaction: agonists, antagonists, partial agonists, and
inverse agonists. Agonists bind to the receptor and elicit a cellular response by causing a conformational
change. Antagonists bind, prevent agonists from binding, and do not elicit any response. A partial agonist
is an intermediate class that upon binding does not invoke the complete agonist conformational change,
but still allows for partial activity; simultaneously, they ‘‘block’’ the receptor from being available for full
agonist binding. When both a full agonist and partial agonist are present, the partial agonist acts as a
competitive antagonist, producing a net decrease in the receptor’s activation. Inverse agonists bind to a
receptor but induce a physiological response opposite to what would be expected from an agonist. The
affinity of a ligand for the receptor is independent of the role: weakly binding full agonists and strongly
binding partial agonists are both known. Biophysical studies indicate that ligand-induced receptor activation generally proceeds by changing the relative orientations of TM3 and TM6 (Nakanishi et al., 2006), with
the intracellular end of TM6 moving away from TM3 by hinging and moving ‘‘up’’ toward the membrane
(Jensen et al., 2001). This modification then affects the conformation of the G protein-interacting intracellular loops of the receptor and thus uncovers previously masked G protein-binding sites. Upon binding of
extracellular ligands such as phytocannabinoids, GPCRs interact with a specific subset of heterotrimeric G
proteins that can then, in their activated forms, inhibit or activate various effector enzymes and/or ion
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Figure 2. Schematic Representation of Signal Transduction by Ligand Interactions with the GPCRs
The state of the receptor in each panel is described therein.

channels. Molecular cloning studies have shown that GPCRs form one of the largest protein families found
in nature, and it is estimated that approximately 1,000 different such receptors exist in mammals; of these,
our focus in this review is limited to two, CB1 and CB2: the cannabinoid receptors (Wess, 1997), but it is likely
that cannabinoids can also interact with other members of the protein family.

A Structural Tour of Cannabinoid Receptors 1 and 2
The human CB1 and CB2 receptors are closely related GPCRs, exhibiting approximately 44% amino acid
similarity overall and 68% homology in the TMs (Munro et al., 1993; Hryhorowicz et al., 2019). Molecular dynamic studies indicate that ligand binding to both CB1 and CB2 occurs through lateral insertion via the lipid
bilayer rather than directly from solution (Reggio, 2010). The most important sequence differences between CB1 and CB2 are in the N-terminal extracellular loop II (ECL2) involved in cannabinoid binding
(Shao et al., 2016), the C-terminal sequence of TM7, and the internal C terminus itself (Montero et al.,
2005). The other key feature in CB receptor is the presence of a toggle switch, whose activation leads to
G protein binding: in CB1 the twin toggle switch involves two residues, F200 and W356 on TM3 and
TM6, respectively; in contrast, CB2 has a single toggle switch residue, W258, on TM6. Changing their relative position opens the two helices like chopsticks revealing the Gi protein binding site. Determining their
status defines whether a ligand is an agonist or antagonist (McAllister et al., 2004). These structural differences define ligand preference: CB1 requires the polycyclic core of the potential ligand to have a C3 alkyl
chain of five or more carbons, whereas CB2 recognizes smaller classical cannabinoids (Figure 1). Similarly,
etherification at C1 leads to CB2-selective compounds. As CB crystal structures have only very recently been
reported, historical, pre-2016, structural work has largely involved homology modeling based on the
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Figure 3. Structure of Synthetic Analogs AM6538, TNB, AM11542, FUB, AM10257, AM12033, and WIN55,212-2

rhodopsin crystal structure (PDB: 1F88), (Palczewski et al., 2000), which shares 21% and 20% homology with
CB1 and CB2, respectively.

Cannabinoid Receptor 1 (CB1)
CB1 receptors, ubiquitous in the CNS, are most highly expressed by the axons and presynaptic termini of
neurons in the amygdala, hippocampus, cortex, basal ganglia outflow tracts, and cerebellum (Baker et al.,
2003). Strongly associated with GABAergic and glutamergic cells, their activation inhibits GABA and
glutamate release, respectively (Baker et al., 2003). CB1 receptor activation has been found to increase
potassium and calcium ion channel activity; consequently, CB1 modulates neurotransmitter release in a
dose-dependent and pertussis toxin-sensitive manner. The receptor can exist as a homodimer, or as a heterodimer or hetero-oligomer complexed with other GPCRs. In addition to the main binding site, the CB1
receptor also possesses an allosteric modulatory binding pocket.

Crystal Structure of CB1
Four crystal structures and two cryoelectron microscopic (cryo-EM) structures of CB1 are available with synthetic cannabinoids (Figure 3). Four are co-crystallized with a ligand: one bound to antagonist AM6538,
one bound to an inverse agonist taranabant (TNB) (Hua et al.; Shao et al., 2016), two bound to a full agonist
(AM11542 and AM841) (Hua et al., 2017), most recently, two Cryo-EM structure: bound to full agonist with
the Gi protein bound (MDMB-Fubinaca, FUB) (Krishna Kumar et al., 2019), and AM841 (Hua et al., 2020).
Crystallization in the presence of a phytocannabinoid remains elusive.
The first crystal structure of CB1 was reported by Liu and coworkers in 2016 as a complex with antagonist
AM6538 (AM6538@CB1, PDB: 5TGZ, Figure 4A, Video S1) (Hua et al., 2016).The authors noted that the
binding pocket of CB1 is quite plastic, as is typical for class A GPCRs, explaining the broad substrate tolerance of the receptor. In the same year, Shao et al. used GPCR engineering and lipidic cubic phase crystallization to determine the structure of the human CB1 receptor bound to antagonist TNB (TNB@CB1, PDB:
5U09, Video S1) (Shao et al., 2016). The conformational flexibility of the ligand binding site is greater in

4

iScience 23, 101301, July 24, 2020

iScience
Review

iScience

ll

OPEN ACCESS

Review

Figure 4. Comparison of CB1 Binding to Different Ligands
Analysis of the ligand binding pocket (A) AM6538@CB1 (5TGZ) and (B) AM11542@CB1 (5XRA). (C) Comparison of the
agonist-bound (blue) and antagonist-bound (light blue) CB1. (D) Superposition of FUB@CB1 (navy) and AM11542@CB1
(blue). Data used to prepare the figures were obtained from Hua et al. (2016), Figures 4A; Hua et al. (2017), Figure 4B; and
Krishna Kumar et al. (2019), Figure 4D.

AM6538@CB1 than in TNB@CB1, leading to a more disordered structure in the former, whereas TNB@CB1
has higher electron densities around the ligand and the critical N-terminal domain providing more specific
structural detail; this is supported by the high B factors in the refined model for AM6538@CB1 (average B =
134.3 A2 for residues 99–112 and B = 119.5 A2 for the ligand), whereas the B factors for TNB@CB1 are far
lower (average B = 61.7 Å2 for residues 100–112 and B = 42.0 Å2 for the ligand) (Shao et al., 2016). However,
both structures remain quite similar in gross morphology providing mutual confidence in the structures and
highlight the CB1-specific feature: the extracellular surface, including the highly conserved membraneproximal N-terminal region differs considerably in conformation from other lipid-activated GPCRs. In
TNB@CB1, the ECL2 and the membrane-proximal N-terminal sequence cooperate to construct a lid
over the orthosteric pocket, essentially isolating the ligand from the solvent. TNB is tightly held in the
pocket, making multiple contacts with both TM1 and TM7 at the TM1–TM7 opening, blocking the entry
of endocannabinoids that prefer to sit deeper in the pocket. This is an unusual feature in a GPCR.
The first agonist-bound CB1 crystal structure was reported in 2017 (AM11542@CB1 PDB: 5XRA) (Figure 4B,
Video S1) (Hua et al., 2020). This structure was largely consistent with that identified by Kobilka et al. in 2019
with the highly potent agonist FUB (FUB@CB1 PDB: 6N4B, Video S1) (Krishna Kumar et al., 2019).
Compared with the antagonists, the extracellular domains of TM1 and TM2 of CB1 move inward and the
intracellular part of TM6 moves outward in the active vis-à-vis the inactive state. These motions shrink
the volume of the orthosteric ligand-binding site by 53%, open the twin toggle switch comprising F200
and W356, and correspondingly increase the surface area of the G-protein-binding region of the receptor,
activating the GPCR. In AM11542@CB1, the N terminus sits over the ligand-binding pocket and is not
directly involved in agonist binding; this differs from the V-shaped loop it adopts in the AM6538@CB1
structure where it caps the binding site (Figure 4C). The C3 alkyl chain of AM11542 occupies a similar position as that of antagonist AM6538@CB1, indicating that the binding differences between agonists and
antagonists is very subtle. The most notable conformational change occurs for TM1 and TM2. In
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CB1

CB2

PDB Code

5XR8

5XRA

6N4B

5TGZ

5U09

6KPC

Ligand

AM841

AM11542

FUB

AM6538

Taranabant

AM12033

6PT0

5ZTY

WIN 55,212-

AM10257

2
Binding affinity Ki

1.14

0.11

0.098

S3837.39

S3837.39

S3837.39

0.038

0.13

0.37

3.3

0.61

(nM)
Hydrogen bond

I267ECL2

Ser2857.39

H1782.65

S1654.57

Y2755.39
W2795.43

p – p interaction

Reference

F942.64

F1702.57

F1702.57

F1702.57

F1702.57

F183ECL2

F268ECL2

F268ECL2

F268ECL2

F268ECL2

F2817.35

F3797.35

F3797.35

F102N-term

F912.61

F1893.25

F1893.25

W3566.48

F1173.36

F1173.36

F1772.64

F1772.64

W2586.48

W2586.48

(Hua et al.,

(Hua et al.,

(Krishna Kumar et al.,

(Hua et al.,

(Shao et al.,

(Hua et al.,

(Xing et al.,

(Li et al.,

2017)

2017)

2019)

2016)

2016)

2020)

2020)

2019)

Table 1. H-Bond and p – p Interactions of Ligands of All Crystal Structures of CB1 and CB2

AM11542@CB1, TM1’s extracellular sequence bends inward by 6.6 A, and TM2 also rotates inward by 6.8 A.
In FUB@CB1, TM2’s rotation repositions F1702.5, F1742.61, F1772.64, and H1782.65, orienting them toward the
pocket in the active conformation to interact with the agonist. FUB association stabilizes CB1 in an active
conformation by forcing open the ‘‘toggle twin switch’’ F2003.36 and W3566.48 residues. The shifting of
W3566.48 leads to the relaxation of the kink at P3586.50 (Figure 4D), straightening out TM6, which opens
up the cytoplasmic binding site allowing the C-terminal a5 helix of GI to bind to the GPCR and initiate
the internal signaling cascade. FUB’s rigidity in forcing these changes makes it a full agonist compared
with the more flexible partial agonists, like THC, that provide for greater receptor flexibility, allowing it
to not be forced into the open state: the critical H-bond and p – p interactions between the ligands and
CB1 that drive these changes are provided in Table 1.

Cannabinoid Receptor 2
The CB2 receptor is closely related to the CB1 receptor (vide supra), with seven transmembrane helices, a
glycosylated N terminus, and the C-terminal helix embedded in the cellular matrix. The discovery in 1993 of
CB2 receptors provided a partial explanation for the immunomodulatory properties of cannabinoids
(Munro et al., 1993). Expressed mainly on immune system cells and the astrocytes and microglia in the
CNS (Mackie, 2008), CB2 activation is associated with neurodefense functions and ensuring maintenance
of bone mass and the reduction of inflammation. CB2 agonists have been explored for slowing neurodegenerative disorders such as Huntingtons chorea and Alzheimer disease (Maccarrone et al., 2007). CB2 receptors function by inhibiting the activity of adenylyl cyclase through their GI /Goa subunits (Bouaboula
et al., 1996; Soethoudt et al., 2017) by coupling to stimulatory Gai/o subunits, causing a rise in intracellular
cAMP levels, and by influencing the Ras-Ref-MEK-ERK pathway, which has a profound effect on mature and
neoteric tissues (Slipetz et al., 1995; Saroz et al., 2019).

Crystal Structure of CB2
The first crystal structure of CB2, bound to high-affinity synthetic antagonist AM10257, was reported by Hua
and coworkers in 2019 (PDB:5ZTY, Figure 3, Video S2) (Li et al., 2019).The C-terminal intracellular helix
adopts an inactive conformation similar to that of antagonist-bound CB1; the extracellular moieties of
antagonist-bound CB2 and CB1 differ, most notably within TM1 and TM2. Unlike its adoption of a V-shaped
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Figure 5. Comparison of the Ligand-Binding Modes of CB1 and CB2
(A and B) (A) Superposition of AM6538@CB1 (5TGZ) (blue) and AM10257@CB2 (5ZTY) (orange) ligand-binding pockets
and (B) conformational difference of F200 and W258 in antagonist bound CB2 and CB1.
(C) Comparison of the ‘‘toggle switch’’ residue conformation in agonist AM12033@CB2 (6KPC) (gold) and AM10257@CB2
(5ZTY) (orange). (D–G) (D) WIN55212-2@CB2 (6PT0) (yellow) orthosteric pocket shows the direct contact of the ligand with
residues F1173.36 and W2586.48 compared with AM10257@CB2 (orange). Comparison of the gross morphology of the receptors:
(E) active CB1 and CB2 (F), active CB1 and inactive CB2, and (G) inactive CB1 and CB2. Data used to prepare the figures were
obtained from Li et al. (2019), Figures 5A and 5B; Hua et al. (2020), Figures 5C and 5E–5G; and Xing et al. (2020), Figure 5D.

loop for direct involvement in ligand binding in antagonized CB1, the N-terminal helix of AM10257@CB2
sits over the orthosteric pocket with no direct involvement in antagonist binding; however, similar to CB1,
ECL2 in CB2 is stabilized by an internal disulfide bond (C174–C179) maintaining the key conformational lock
holding the binding site in the ligand-binding conformation.
There are major structural differences between the two ligand-bound receptors, despite the structural
similarity of AM10257 and AM6538. Instead of adopting the extended conformation of AM6538
in AM6538@CB1, AM10257 assumes a more constrained binding pose in AM10257@CB2. In
AM10257@CB2, the ligand forces TM3 and TM4 over by 6.1 Å relative to AM6538@CB1, using the pyrazole
ring as a common reference point (Figure 5A). Similarly, the extracellular moieties of TMI and TM2 collapse
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toward the ligand binding site allowing F872.57 and F912.61, to form hydrophobic interactions with
AM10257. In contrast to the horizontally extended arm of AM6538 in AM6538@CB1, that of AM10257
in AM10257@CB2 assumes a nearly vertical pose. This likely all relates to the differential behavior of the
N-terminal sequence in the two receptors: in CB1 the adopted V-shaped loop inserts into the cannabinoid
binding pocket, whereas in CB2 it remains extended and does not interact with the pocket. The other main
difference in antagonist-bound CB2 and CB1 structures is the toggle switch residue W2586.48. AM10257
confines the side chain of W2586.48 limiting the outward movement of TM6, whereas in AM6538@CB1
the ligand drives TM1 and TM2 apart. F200 functions as a latch to restrict the movement of W356 and locks
CB1 in the inactive state (Figure 5B). Computational chemistry has also contributed to our understanding of
the receptor. Docking studies involving structurally related CB2 agonist MRI2594, and antagonist MRI2687
(Ogawa et al., 2015), which differ only by the length of one side chain, demonstrate the mechanism of activation of the toggle switch residue W2586.48. W258 is a highly conserved residue in class A GPCRs and has
been reported to have a crucial role in GPCR activation (Lin and Sakmar, 1996). This observation not only
supports the identification of W2586.48 as a key residue but also demonstrates the very fine line between the
order of interaction involved in the binding of CB2 agonists and antagonists. The antagonist-binding motif
in CB2 resembles the agonist-binding motif in CB1, especially in the conformations of the N termini. In addition, the volume of the CB2-antagonist binding pocket (447 Å3) is closer to that of activated AM11542@CB1
(384 Å3) than to that of antagonized AM6538@CB1 (822 Å3). This provides the structural basis for the observation that CB2 antagonists are often CB1 agonists (Ogawa et al., 2015), highlighting the yin-yang relationship between CB1 and CB2.
During the preparation of this review, Hua and colleagues reported a crystal structure of the agonist
AM12033 (Figure 3, Video S2)-bound CB2, obtained from X-ray diffraction data (PDB: 6KPC).(Hua et al.,
2020) It was noted that the main interactions in AM12033@CB2 are hydrophobic and aromatic in nature (Table 1). The binding pockets associated with agonist AM12033 and antagonist AM10257 were largely
similar, but the inward movements of extracellular parts of TM1, TM4, and TM7 lead to the agonist’s binding pocket being more compact. The W2586.48 ‘‘toggle switch’’ experiences an especially strong shift in
AM12033@CB2 (Figure 5C) (Hua et al., 2020).
Xing and co-workers reported the electron microscopic structure of CB2 bound to a more potent agonist,
WIN55,212-2 (Figure 3; PDB: 6PT0, Video S2) (Xing et al., 2020). Although this structure shows near identity
to the AM12033@ CB2, there were subtle differences: AM10257 penetrates deeper into the binding pocket
(ca. 2.8 Å) compared with WIN55,212-2, resulting in different conformations for toggle switch W2586.48. The
slight rotation of F1173.36 permits W2586.48 to interact only weakly with WIN 55,212-2, forcing it 1.2 Å further
away from the ligand than in the case of AM10257 (Figure 5D). The consequent outward movement of the cytoplasmic end of TM6 further widens the G protein binding site. Even minor changes arising from the steric effects
of CB2 ligands on W2586.48 play a crucial role in determining the relative agonism of CB2 ligands (Figure 5D).
Although AM841@CB1 and AM12033@CB2 are similar, the receptors exhibit distinct characters in terms of
ligand and G protein selectivity and activation process (Figures 5E–5G). The single residue difference in
ICL-2 (L222 in CB1 and P139 in CB2) may contribute to the G protein coupling diversity of the cannabinoid
receptors; whereas CB2 is Gi specific, CB1 can bind other G proteins such as Gs (G protein-stimulating adenylate cyclase), and Gq (G protein-activating phospholipase C and G protein-increasing cytosolic Ca2+).
The high degree of structural similarity in the orthosteric binding pockets between agonist-bound CB2
and CB1 imposes substantial challenges for receptor-selective agonist design.

Homology Modeling
As discussed, it is only very recently that X-ray and cryo-EM-derived structures of the cannabinoid receptors
have been available for analysis. Lacking these models, various computational techniques such as 3-dimensional quantitative structure-activity relationship (3D-QSAR), pharmacophore mapping, homology
modeling, docking, and virtual screening techniques have been used extensively to derive information
about the CB receptors from the crystal structures of related proteins, such as rhodopsin. The first threedimensional model of a human cannabinoid receptor was constructed by Mahmoudian using bacteriorhodopsin as the structural template, with the aid of the SYBYL and MOPAC packages in 1997 (Mahmoudian,
1997). THC was then docked into the internal cavity utilizing AutoDock. This example shows the challenges
in this type of work: the software and computing power 23 years ago was greatly inferior to modern tools,
and the available crystal structure of the base protein, bacterial rhodopsin, was not even a GPCR protein
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Figure 6. General CB1 Receptor Inverse Agonist Pharmacophore Model in Relation to the Putative CB1 Receptor
Side Chain Residues in Receptor-Ligand Interactions
Figure adapted from Lange and Kruse (2005).

leading to unavoidable error. However, it was the best that could be done at the time, and some of his findings, such as the criticality of the phenolic hydroxyl of THC for CB1 binding, have been validated by later
structure-activity relationship (SAR) studies (Huffman et al., 1996).
In 1998, Shire and colleagues (Rinaldi-Carmona et al., 1998) used the WHATIF (Vriend, 1990) program for
sequence manipulations and model energy refinement and SYBYL modeling packages based on the 1998
refined crystal structure of GPCR bovine rhodopsin (PDB: 1F88) (Krebs et al., 1998). The challenge in homology
modeling without a crystal structure is in validating the result. Consequently, it can be useful to generate multiple
versions from different base proteins. In this vein, Latek and coworkers developed structures of both the CB1 and
CB2 receptors based on the b2-adrenergic receptor (PDB: 3D4S) (Latek et al., 2011) and compared the result with
both rhodopsin-based models. All three models predicted the rough morphology of the orthosteric pocket, and
have been broadly validated by crystallography (Durdagi et al., 2010).
An example of the success of this approach to advance experimental SAR work is provided by Lange and
coworkers, who used computational methods to derive a general model of the five structural requirements
of a CB1 inverse agonist pharmacophore (Figure 6): two aromatic moieties (A and B), a central unit (C), a
hydrogen bond acceptor unit (D), and a cyclic lipophilic domain (E) (Lange and Kruse, 2005; De Azevedo
and Russo, 2018).
However, there were clear limitations. Rhodopsin-based models lack the key N-terminal domain that
shields the bound ligand from the solvent in CB1. To compensate, Reggio et al. used the human S1P1 receptor, with very high (62%–64%) sequence homology with the CB1 receptor in their TMs, for homology
modeling (Hurst et al., 2013). They identified the two features of the S1P1 X-ray crystal that are particularly
relevant for CB1 and CB2: an extracellular pocket that is closed off to the solvent and a gap between TM1
and TM2 that allows a ligand to pass from the lipid bilayer into the binding pocket. The eventual CB1 crystal
structure determined by Liu in 2016 (Hua et al., 2016) proved very similar to this obtained homology model.
The model was used to demonstrate that ligands such as AEA and THC access the CB1 binding site from
the membrane by passing between residues F1742.61 and F1772.64, which facilitate transit by forming pp
interactions with the ligands (Jakowiecki and Filipek, 2016). This observation remains accurate.
Although the 2016 release of the first CB1 crystal structure increased the scope of modeling opportunities,
homology modeling has continued to be an important approach to obtain accurate 3D structures in the
absence of experimental structures, especially for the phytocannabinoids. In 2018, Liu and coworkers
used a combination of sequence alignment and homology modeling of the S1P1 crystal structure (PDB:
3V2W) (Hanson et al., 2012) to investigate the binding modes of rimonabant analogs as selective inverse
agonists/antagonists for CB1 (Liu et al., 2018). Their CB1 model was validated by superimposing the model
and the crystal structure (PDB: 5TGZ). Docking analyses showed that the hydrophobic interactions between
the ligands and the hydrophobic pockets of CB1 account for most of the binding affinity. The CB1 K1923.28
on TM3, known to be important for ligand binding, engaged in indirect, rather than direct, interactions with
antagonists to keep the inactive-state CB1 stable through a salt bridge with D1762.63 on TM2. Another
recent example is the high-throughput screen of over 3,000 CB1 antagonists by Liu et al., who modeled
CB1 from the rhodopsin template. Multiple CB1 homology models were tested, and the best one was
selected for use in virtual screening (Liu et al., 2014).
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Homology modeling has been more important for CB2, and with the continuing lack of an agonist-bound
form, remains essential. The CB2 model constructed from b1AR/b2AR/D3R has afforded better predictions
for pre-screening compared with those built from the seven other GPCR crystal structures
examined, namely, SMO (Wang et al., 2013), bovine rhodopsin (Palczewski et al., 2000), CXCR4 (Wu
et al., 2010), M2MAR (Haga et al., 2012), D3R (Chien et al., 2010), b2AR (Cherezov et al., 2007), A2AAR
(Lebon et al., 2011), H1R (Shimamura et al., 2011), S1P (Hanson et al., 2012), and b1AR (Warne et al.,
2011). It is also suggested that sodium ions may reduce the binding affinity of endogenous
agonists or its analogs (Feng et al., 2014). After the crystal structure of CB1 was reported in the literature
in 2016, several studies used it as the basis for homology models of CB2. Makriyannis and coworkers developed a series of fluorescent ligands to better understand CB2 receptor expression and signaling to accelerate drug discovery (Mallipeddi et al., 2017). The release of the first CB1 crystal structure alignment
(MUSTANG) of the AM1336@CB2 homology model showed an root-mean-square deviation of 2.10 Å
and over 193 aligned residues with 47.7% sequence homology (Mallipeddi et al., 2017). AM11542@CB1
(PDB: 5XRA) was also used for the generation of a homology model of a CB2-ligand complex for further
computational studies (Dolles et al., 2018). As noted, this CB1 agonist provided a model of an antagonized
CB2 system.
Latek et al. used structures of a2AR, b2AR, and b1AR as templates for homology modeling of CB1 and
CB2 to bound THC and AEA in their crystal structures, combining induced docking of THC@CB1 and molecular dynamics simulations of the crystal structure of THC@b2-adrenergic receptor to provide insight
(Latek et al., 2011). They revealed that the conformation of the centrally located W3566.48 and F2003.36
toggle switch differentiates between agonists and antagonists: nonselective agonists THC and AEA
changed the positions of these two residues in both receptors relative to the empty receptor. THCs
hydroxyl group formed a hydrogen bond with the d-carboxylic acid E2735.37 in THC@CB1, sliding its alkyl
tail slid into the hydrophobic channel between TMs 3, 6, and 7 close to the toggle switch (Figure 7A). In
THC@CB2, THC forms the exact same hydrogen bond with E2735.37, but the alkyl chain sits in a slightly
different position between TMs 3, 5, and 6, but still leaving it close to the switch. The C5-6-fused bicycle
of the ligand interacts with F1772.64 (s-p interactions, Figure 7B) to lock-in this conformation. Endocannabinoid AEA@CB2 adopts a similar overall binding mode, with the nitrogen atom forming a hydrogen bond
with S1935.42. The ligand’s alkyl tail extends along the hydrophobic pocket defined by TM2 and TM3, interacting with phenylalanines F1742.61, F1772.64, and F1893.25 and the hydrophobic face of K1923.28 (Figure 7B).
Consequently, although experimentally validated structures are now available, homology modeling will
remain an important approach for investigating interactions between ligands and the CB2 receptor and
is expected to continue in this crucial role for years to come.

Interactions between CB1/CB2 and the Phytocannabinoids: Case Studies
As we have no experimental structures of phytocannabinoids bound to CB1 or CB2, but do have them
bound to other GPCRs, a combination of computational and experimental structural biology is required
to make inferences about their binding and to determine the design of new ligands. The rest of the review
is devoted to discussing the work done in this field to date for the most important cannabinoids.

D9-Tetrahydrocannabinol (THC)
THC exhibits partial agonist activity at CB1 (Ki = 10 nM) and CB2 receptors (Ki = 24 nM) (Howlett et al., 2002).
A detailed description of the downstream biological effects of THC binding to CB1 is beyond the scope of
this review, but it downregulates secondary messenger molecule cAMP by inhibition of adenylate cyclase.
This results in the observed psychotropic effects such as euphoria, relaxation, and anti-nociception (Hua
et al., 2016). CB1 agonism by THC has broader pharmacological implications as it is used therapeutically
as an analgesic, antiemetic, and anticonvulsant across the world. Being a partial rather than a full agonist
of CB1, THC demonstrates lower cytotoxicity compared with synthetic cannabinoids like FUB, and consequently has a better safety profile.
When Hua et al. examined THC@CB1 using docking studies based on their CB1 crystal structure (PDB: 5TGZ);
(Hua et al., 2020) they predict that THC mainly interacts with ECL2, the N-terminal loop, and TM3, TM6, and
TM7, but not with TM1 or TM2 (Figure 8A).The THC ring system resides between the N-terminal loop and
ECL2, participating in p-p interactions with F268ECL2, whereas the carbon chains extend into the long hydrophobic pocket to interact with TM3, TM6, and TM7. In a second docking study of THC@CB1 based on the TNB@CB1
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Figure 7. THC and AEA Bind to Both CB1 and CB2
Nonselective agonists THC and AEA bound to (A) CB1 and (B) CB2 in complexes characterized by the lowest energies;
both top-down and side-on views are provided. Interactions involving p orbitals are shown as orange solid lines, and
hydrogen bonds are shown as green dashed lines. Figure reproduced from Latek et al., (2011), with permission.

crystal structure discussed earlier, Shao and coworkers predicted that the tricyclic core of THC positions between
TM1, TM2, and TM7 (as with TBN) (Shao et al., 2016), with the C3 alkyl chain overlapping with the chlorophenyl
moiety of TBN and extending toward toggle residue W3566.48 (Figure 8B). Finally, C3556.47 on the external face of
TM6 can form a covalent adduct with a THC analog that possesses a thiol at the end of the C3-pentyl chain
(Picone et al., 2005). This obviously requires a rotation of TM6 during CB1 activation and consequent disruption
of the packing around W3566.48; ligand binding is clearly dynamic. One caveat to these calculations, however, is
that the inactive structure of CB1 used in these studies is not ideal for predicting high-affinity agonist interactions
as an agonized binding site must access a different conformation in the presence of agonists to induce a conformational change to allow for Gi protein binding. In the third study by Hua et al., cited previously, the active crystal
structure of CB1 was used (PDB: 5XRA). The binding mode of THC was seen to resemble that of AM11542@CB1
(Figure 8C). The binding affinity of THC for CB1 results mainly from a combination of hydrophobic and aromatic
interactions and excellent shape complementarity, rather than dipole-dipole or hydrogen bonding, with residues from ECL2 and TM3, TM5, TM6, and TM7. The tricyclic THC ring system forms p–p stacking with
F268ECL2, F3797.35, F1893.25 and F1772.64, and the phenolic -OH at C1 forms a hydrogen bond with S3837.3.
The alkyl chain of the THC extends into the long channel formed by TM3, TM5, and TM6, participating in hydrophobic interactions with L1933.29, V1963.32, Y2755.39, and L2765.40. THC, with a shorter alkyl chain (C5) compared
with AM11542, shows a similar interaction. Daines and co-workers in 2018 looking for other docking sites on CB1
failed to identify any and reiterated the importance of residues 380–384 for binding (Sabatucci et al., 2018).
In 2019, Jung docked THC onto structures of both the inactive and the now available active conformations
of CB1 (PDB: 5TGZ and 5XRA, respectively) and carried out molecular dynamic simulations to predict
the binding poses of THC in the orthosteric ligand-binding site (Jung et al., 2018). THC docked well and
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Figure 8. THC and TNB Adopt Different Comformations when Bound to CB1
(A–C) (A) Chemical structures and predicted binding poses of THC with inactive structure, (A) PBD: 5TGZ and (B) PDB:
5U09 (15) (transparent magenta sticks), and (C) with active structure PDB: 5XRA. THC (pink) and TNB (light green). Data
used to prepare the figures were obtained from Hua et al., 2016 Figure 8A; Shao et al. (2016), Figure 8B; and Hua et al.,
2017, Figure 8C.

adopted similar configurations in both conformations and was consistent with the homology modeling
work discussed earlier. When THC was bound to the active conformation, it stably interacted with F200.
The molecular mechanics Poisson-Boltzmann surface area (MM/PBSA) binding energies for the inactive
and active conformations of CB1 with THC were 20.87 and 30.05 kcal/mol, respectively, supporting
THC’s role as a partial agonist (Pertwee, 2008).
Tham et al. replicated the study, docking THC to the same crystal structures. In the agonist-bound receptor
model 5XRA, THC interacted with TM2, TM3, TM5, and TM7, whereas in the antagonist-bound model
(5TGZ), THC showed weaker interactions with TM1, TM3, TM4, TM6, and TM7. The only interaction maintained in both conformations was between THC and TM3 T1973.33. Ligand affinity docking score values estimated by AutoDock for inactive 5XRA and active 5TGZ structures were 8.7 and 10.4 kcal.mol1, respectively, in agreement with Jung.
Kumar et al. proposed that the lack of toggle switch interaction explains why THC has only partial CB1
agonist activity compared with the full agonist AM series (Krishna Kumar et al., 2019). Their docking calculations of THC@CB1 yield several poses where the terpenoid ring aligns well with that of the ligand in
AM11542@CB1 (Hua et al., 2017); however, THC’s C3 alkyl chain was more flexible, able to both occupy
the hydrophobic cavity, coincident with the p-fluorobenzyl group of full-agonist FUB, and to adopt a downward conformation where it points toward the toggle switch to activate the receptor. This seems to indicate
that the conformational flexibility of THC in the orthosteric pocket likely modulates both its affinity for, and
activating ability of, CB1, a characteristic that presumably makes it safer than the more rigid and potent ‘‘always-on’’ synthetic cannabinoids.
The computational study of the binding of THC to CB2 is more limited, but Vijayakumar and co-workers
(Vijayakumar et al., 2019) determined the energetic docking scores of various with the receptor. They indicated that THC possesses superior docking scores (5.379 kcal/mol) compared with known agonists such
as TNB, HU-308, and rimonabant.

Cannabidiol (CBD)
CBD is the second most abundant phytocannabinoid present in cannabis (Mechoulam et al., 2007) and accounts for up to 40% of dry mass in some cultivars. It is a partial agonist of the CB2 receptor, although it can
bind to other, non-cannabinoid receptors, too. Preliminary clinical data suggest that CBD may ameliorate
the symptoms of anxiety, cognitive and movement disorders, pain, and epileptic seizures. As of 2019, the
specific mechanisms of action for its biological effects remain unclear. CBD has low affinity for the CB1 orthosteric site (McPartland et al., 2007), and is a CB1 antagonist (Thomas et al., 2007), but Laprairie et al. have
reported that CBD might largely behave as a CB1 negative allosteric modulator (NAM) of THC and 2-AG
agonism (Laprairie et al., 2015).
In 2018, Sabatucci and colleagues (Sabatucci et al., 2018) performed an in silico docking study on the crystal
structure of CB1 to find putative allosteric sites for CBD, and to examine its binding affinity. They identified
three different sites based on a cluster analysis and calculated the binding energy (Table 3):
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TM

THC

CBD

5XRA
CB1

5TGZ
CB2

1

CB1
M103

5XRA
CB2

CB1

5TGZ
CB2

CB1

Nt

CB2
S19Nt

K23Nt

K23Nt
M109Nt
Q1151.31
Q1161.32
I1191.35

F872.57

2

F872.57

S902.60
F912.61
F1702.57
F1742.61
F1772.64

F1772.64
H1782.65

F183ECL2
T1143.33

3

L182ECL2

L182ECL2

F183ECL2

F183ECL2

T1143.33

T1443.33

L1933.29
T1973.33

T1973.33
F2684.77

4

F2684.77
W1945.43

5
W2795.43

W2586.48

7

L3596.51
M3636.55
A2827.36

Helix8

A2827.36
L2897.43

F3797.34
S3837.39

F3797.34
S3837.39

Table 2. Summary of CB1 Agonist-Bound (5XRA) and Antagonist-Bound (5TGZ) Amino Acid Residues Interacting
with Cannabinoid THC and CBD in AutoDock

1. Pocket 1: in the transmembrane region between TM2 and TM4, ligand binding happens through the
conserved residue W241 (TM4), hydrophobic residue F237 (TM4), and an electrostatic interaction
with protonated H154 (TM2).
2. Pocket 2: between TM1, TM7, and intracellular helix 8.
3. Pocket 3: in the N-terminal region of CB1, partially overlapping the orthosteric site. It comprises the
residue C107; however, interactions in this region were not completely characterized.
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Pocket 1

Pocket 2

Pocket 3

Orthosteric Site

DG (kcal/mol)

DG (kcal/mol)

DG (kcal/mol)

DG (kcal/mol)

THC
CBD

8.34
7.75

–

7,39

8.15

AEA

9.55

2-AG

9.41

Table 3. Binding of THC, CBD, AEA, and 2-AG at the Various Potential Pockets on CB1

4. The orthosteric site: in the inactive conformation, the volume of the ligand-binding pocket is around
50% greater than in the active conformation.
Examining THC as a control, they found, consistent with all the studies mentioned earlier, that THC binds
only to the orthosteric site. No crystal structure of CBD@CB1 is available to answer this question, and it is
possible that all three binding sites are in dynamic equilibrium (Figure 9A).
In their 2019 article discussed earlier using both the agonist- and antagonist-bound CB1 crystal structures,
Tham et al. (2019) also studied potential CBD@CB1 interactions. CBD behaved as a NAM and occupied a
ligand binding site in the antagonist-bound CB1 receptor model (5TGZ) that was separate from the orthosteric agonists tested. Table 2 summarizes the findings of Tham et al. CBD appears to have fluid affinity for
both the allosteric (inactive state, R) and orthosteric (active state, R*) sites at CB1 receptors, depending on
whether another ligand is activating the receptor or not. Ligand affinity values estimated for the 5XRA-CB1
and 5TGZ-CB1 receptor models were 7.1 and 9.7 kcal.mol1, respectively. On the basis of these data, it
is evident that CBD has a high affinity for an allosteric site in the outer vestibule of the antagonist-bound
CB1 receptor. To analyze the effect that CBD binding has on the activated receptor, a 50-ns molecular dynamics simulation was performed by Chung and coworkers on the CBD@(THC@CB1) complex (Chung
et al., 2019). CBD binding leads to coordinated opening of both the cytoplasmic and extracellular pockets,
allowing improved access for ligands in the binding site while closing off the Gi binding site. Hydration of
CBD’s exposed terpenoid ring leads to folding of the membrane proximal region, which both promotes
partial entry of CBD into the orthosteric binding site in the presence of THC, which adopts an L-shape
conformation to accommodate the new ligand (Figure 9B). To expand the orthosteric site to accommodate
two small molecules, TM1 and TM2 pincer apart on the extracellular side, whereas TM6 and TM7 do the
same on the intracellular side (Figure 9C).
The N-terminal loop formed by the C98-C107 disulfide bond then closes over CBD as it enters deeper into
the binding site. This cap is anchored by a semi-organized water blanket that seals the pocket behind CBD.
From here, CBD tightens its affinity for the site by interacting with ECL2 and the N-terminal loop, forming
hydrogen bonds with I267 and well-organized capping water molecules. Despite CBD’s ability to bind to
multiple sites of CB1 in the presence of THC, this work makes a strong argument that the preferred binding
site is located at the entry to the orthosteric binding site: CBD follows THC into the receptor, turning the
GPCR off just as the THC turns it on.
Docking studies conducted on a CBD@CB2 homology model built on AM11542@CB1 and AM6538@CB1
display partial agonism and orthosteric site binding through key interactions with residues K23Nt, F912.61,
L182ECL2, FECL2183, and A2827.36 in the 5XRA model. The two different models provide slightly different
conformations, with estimated binding energy being 8.9 and 9.4 kcal/mol, respectively (Table 4)
(Tham et al., 2019). This is different from the preferences of THC@CB2 (analyzed by homology modeling
of both AM11542@CB1 and AM6538@CB1, both producing similar results), which interacts with only two
of the same key residues. Ligand affinity of THC estimated for homology modeling of CB2 with the
5XRA and 5TGZ receptor models was 9.4 and 8.9 kcal.mol1, respectively.
There are isolated reports of the modeling of various other phytocannabinoids such as CBG (El-Darawy et al.,
1972) and CBN (El-Darawy et al., 1972). However, the work on the molecular modeling of these systems remains
very preliminary, although it will likely greatly expand in the coming years. We anticipate that an update on this
review will likely focus more on these minor cannabinoids as much of the pharmacological activity ascribed to
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Figure 9. CBD and THC May Bind Simultaneously to CB1
(A–C) (A) Orthosteric site (O) and the three potential allosteric binding pockets in CB1 PDB: 5TGZ. (B) Solvent
rearrangement around CBD in the agonist-bound CB1. CBD (orange), THC (yellow), and water molecules within R3 Å in
the active conformation of the CB1R at 0, 25, and 50 ns of simulation; (C) coordinated movement observed in the active
conformation of CB1 during 50 ns of simulation. Data used to prepare (A) was obtained from Sabatucci et al., 2018; Figures
9B and 9C are reproduced from Chung et al. (2019) under Creative Commons Rights.

cannabis might lie with these minor compounds rather than exclusively with the two major cannabinoids. However, one of the ‘‘major’’ minor cannabinoids, THCV, has drawn some attention (Gill, 1971).

D9-Tetrahydrocannabivarin (THCV)
THCV is structurally similar to THC, with the only difference being two fewer carbons in the carbon tail: both
molecules share similar traits, binding affinities, and metabolic derivatives. However, unlike THC, THCV has
proposed anti-obesity activity. THCV’s activity is complicated: it is implicated as a cannabinoid receptor
antagonist by competitively inhibiting THC@CB1 formation, although other evidence implies that THCV
may also be an indirect agonist (Englund et al., 2015).
In 2018, as part of their extensive analysis, Jung and coworkers docked THCV to both the inactive and active
conformations of CB1 as extracted from the crystal structures of 5TGZ and 5XRA, respectively (Jung et al.,
2018). THCV docked well to both conformations, exhibiting similar binding poses in the orthosteric ligandbinding site, with binding affinities to the inactive and active conformations (MM/PBSA) being 21.02 and
28.03 kcal,mol1 respectively. The only difference between THCV and THC was that the pentyl side chain
of THC protrudes into the sub-pocket of the binding site, which does not occur during THCV binding (Jung
et al., 2018). Both THC and THCV interacted more favorably with the active conformation than the inactive
conformation, although THCV showed lower affinity for the active conformation than THC.
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THC

CBD

CB2

CB2

5XRA

5TGZ

5XRA

S19Nt

1
K23Nt
2

5TGZ

F872.57

K23Nt

F872.57

S902.60
F912.61

FECL2183
3

T1143.33

L182ECL2

FECL2183

FECL2183

T1143.33

5

W1945.43

6

W2586.48

7

L182ECL2

A2827.36

T1143.33

A2827.36
L2897.43

Table 4. Summary of CB2 Agonist-Bound (5XRA) and Antagonist-Bound (5TGZ) Amino Acid Residues Interacting
with Cannabinoid THC and CBD

In the inactive conformation of THCV@CB1, THCV interacts with the same three residues as THC: F102,
F379, and S383, but it also interacts with three other residues: M103, I105, and F268. These additional hydrophobic attractions are sufficiently weak that THC retains stronger affinity for the orthosteric binding site
(Figures 10A and 10B). In the active conformation, both THC and THCV interact with five common residues:
F170, L193, V196, F268, and F379, whereas THCV also binds to F177. Both ligands are strong binders to the
orthosteric site, although THC does show more potent activity (Jung et al., 2018).

Tetrahydrocannabutol (THCB) and Cannabidibutol
One of the essential parameters that can affect the biological activity of THC-like cannabinoids is the length of
the C3 alkyl chain. A minimum of three carbons are necessary for receptor binding; activity then increases with
increasing number of carbons up to a maximum of eight carbons; for n > 8, activity begins to decrease again
(Bow and Rimoldi, 2016). Cannazza and colleagues have recently reported two new phytocannabinoids, tetrahydrocannabutol (THCB) and cannabidibutol, both with linear alkyl side chains containing four carbon atoms (Citti
et al., 2019a; Linciano et al., 2020). THCB has thrice the affinity of THC for CB1, with unchanged affinity for CB2
(Bow and Rimoldi, 2016). Docking simulations of THCB@ CB1 found binding poses similar to those exhibited by
THC and THCV. The main difference between the three ligands was observed in the position of the aliphatic side
chain: the butyl chain of THCB does not extend down the TM3-TM5-TM6 tunnel like the pentyl chain of THC
(Figure 10C); instead, like the propyl chain of THCV it binds to the small hydrophobic subpocket located near
the entrance of the tunnel (Figure 10D). This leads to THCB’s optimal hydrophobic interaction with F170,
F200, and L387, accounting for its exceptional affinity for the CB1 receptor (Figure 10E).

Tetrahydrocannabiphorol (THCP) and Cannabidiphorol (CBDP)
In late 2019, Cannazza and coworkers reported the isolation of two additional phytocannabinoids: tetrahydrocannabiphorol (THCP) and cannabidiphorol, both with C7 linear alkyl side chains (Citti et al., 2019b).
THCP has exceptional affinity to both CB1 and CB2, with a Ki of 1.2 and 6.2 nM, respectively, 33-fold the affinity of THC for CB1 and 13-fold higher than THCB. THCP binds to the active conformation of CB1 in an Lshaped pose, approximating that of THC in the presence of CBD (Chung et al., 2019), with the tetrahydro6H-benzo[c]chromene ring system occupying the hydrophobic orthosteric pocket. The resorcinyl moiety
participates in two edge-to-face p-p interactions with F170 and F268, and the C1 hydroxyl group hydrogen
bonds with S383 (Figure 10F). Interestingly, the heptyl chain at C3 extended into a long hydrophobic tunnel
formed by L193, V196, Y275, I271, L276, W279, L359, F379, and M363, formed by TM3, TM5, and TM6, along
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Figure 10. Binding Poses of CB1 Ligands after 1-ms Molecular Dynamics Simulations
(A–G) THC and THCV were bound to the (A) inactive and (B) active conformations of CB1 receptor. Docking pose of (C)
THC, (D) THCV, (E) THCB, and (F and G) THCP in complex with CB1 receptor (PDB ID: 5XRA). Data used to prepare Figures
10A and 10B were obtained from Jung et al. (2018), and for Figures 10C–10G from Citti et al. (2019a, 2019b).

its entire length, maximizing the hydrophobic interactions with the residues along the side of the channel
(Figures 10F and 10G). In contrast, the tunnel is only partially occupied by the shorter pentyl chain of THC,
helping to account for THCP’s far higher affinity. This orientation is also different than the pose predicted for
the shorter alkyl chain homologs, THCV and THCB, where the chain sits in the side hydrophobic pocket
instead. In a murine model, THCP showed promising pharmacological activities associated with CB1 agonists including reduced motility, analgesia, catalepsy, and decreased rectal temperature.

Endocannabinoids (AEA and 2-AG)
Finally, the binding interactions between the endogenous cannabinoids have received some attention (Stella
et al., 1997; Maccarrone, 2019). The first endogenous cannabinoid, AEA, was isolated from porcine brain (Devane et al., 1992) and was shown to bind to the CB1 receptor with high affinity. 2-AG, a second endogenous
cannabinoid, was isolated from intestinal tissue of mice (Mechoulam et al., 1995). 2-AG has been found present in the brain at concentrations 170 times greater than AEA. Furthermore, 2-AG acts as a full agonist, producing the characteristic effects associated with cannabinoid agonists (Stella et al., 1997).
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Figure 11. Endogenous Cannabinoids Interact with the CB2 Receptor
(A) Molecular dynamics simulations of 2-AG binding to the membrane-embedded CB2 receptor. Predicted binding poses
of (B) AEA and (C) 2-AG. Figure 11A is reproduced from Hurst et al. (2010) with permission; data used to generate Figures
11B and 11C were obtained from Hua et al.

AEA has low CB2 affinity, whereas 2-AG binds strongly to CB2 (Mechoulam et al., 1995; Sugiura et al., 1995).
Microsecond timescale molecular dynamics simulations of the interaction of 2-AG with CB2 receptor in a palmitoyl-oleoylphosphatidylcholine lipid bilayer have provided insight into the mechanism of binding. 2-AG partitions out of bulk lipid at the TM6/7 interface, and then enters the CB2 receptor binding pocket by passing between TM6/7 (Figure 11A), similar to the phytochemicals. The entrance of the 2-AG head group into the CB2
binding pocket is sufficient to trigger breaking of the intracellular TM3/6 ionic lock and cause the movement
of the TMH intracellular end away from TM3 (Hurst et al., 2010). Both AEA and 2-AG are predicted to adopt
a C-shaped conformation and occupy a similar position in the inactive structure as THC (PDB; 5TGZ; Figures
11B and 11C), but their longer shape means that their hydrophilic heads rest between the N-terminal loop
and ECL2 and their long tails stretch deeper into the hydrophobic tunnel, like THCP (Hua et al., 2016).

Conclusion and Perspectives
As the residual stigma associated with cannabis use is reduced by spreading legalization, and as additional
clinical reports on phytocannabinoid activity begin to proliferate, it is increasingly essential to understand
the molecular basis of activity. This is clearly not restricted to the CB1 and CB2 alone, but preliminary work
has focused on these obvious candidates. The structural biology work outlined in this article, both experimental and computational, has largely supported the hypotheses laid out in the point mutation studies,
and progress has been very rapid despite the fact that the crystal structures of any of the cannabinoid
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receptors are no more than 4 years old at the time of writing. Far from being associated with only psychoactive effects, the cannabinoid binding sites have been found to be the major mediators of important physiological functions such as analgesia, hunger, emesis, and immunochemical responses. Many of these effects likely arise from a complicated interplay of agonism and antagonism of CB1, CB2, and other related
GPCRs; the activation profiles of the major cannabinoids are clearly very poorly understood. However, a far
more fruitful area of future development will likely involve detailed studies on the minor phytocannabinoids
(>150 at time of writing), some of which have activity orders of magnitude higher than that of THC and CBD.
The field is expected to advance rapidly in the coming months and years as additional cryo-EM and X-ray
structures are solved; it is likely a matter of time before structures in the presence of key phytocannabinoids
are available. The dynamism of these receptors, their interconversion between agonized and antagonized
states, and a clear determination of the mechanism of action of partial agonists might be clarified by the
complementary application of NMR-solution-phase structural analysis, biophysics techniques, and computational modeling. Much of the fundamental work has been done, but greater clarity regarding the relationship between structure and function remains a tempting challenge. In this review we seek to demonstrate
that computational and experimental approaches work exceedingly well together and note with optimism
that combined studies are becoming ever more common; we hope that this continues to be the case. This is
especially important as the role of the cannabinoids in physiology likely extends far beyond the cannabinoid receptors, and we expect that future studies will also report on their interactions with other GPCRs
and related proteins as we better understand their fascinating pharmacology.
A better understanding of these interactions will improve our understanding of neuropsychopharmacology
and not only will help guide the development of new more selective drugs, and new cannabis cultivars with
specific minor cannabinoid profiles to better realize the therapeutic potential of cannabis, but also will provide greater insight into the specific binding modes and interdependency of the GPCRs. We hope an update on this review will provide a much broader scope and far greater insight into these other drugs.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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